Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

Fig. 3

Anti-PD modality: Tumor-site immune modulation therapy. Anti-PD therapy is mechanistically distinct from anti-CTLA-4 therapy: the latter affects immune responses more systemically, whereas anti-PD therapy primarily targets its actions at the tumor site. Anti-PD modality is thus capable of repairing tumor-induced immune defects, ultimately leading to resetting of the anti-tumor immunity to a desirable level. TN: Naïve T cells; TE: T effector cells; Tm: memory T cells; DC: dendritic cells

Back to article page